Bruker Corporation (NASDAQ:BRKR) Declares Quarterly Dividend of $0.05

Bruker Corporation (NASDAQ:BRKR) declared a quarterly dividend on Thursday, February 19th. Investors of record on Monday, March 23rd will be paid a dividend of 0.05 per share by the medical research company on Tuesday, April 7th. This represents a c) annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Monday, March 23rd.

Bruker has increased its dividend payment by an average of 0.0%per year over the last three years. Bruker has a dividend payout ratio of 7.3% indicating that its dividend is sufficiently covered by earnings. Analysts expect Bruker to earn $3.15 per share next year, which means the company should continue to be able to cover its $0.20 annual dividend with an expected future payout ratio of 6.3%.

Bruker Trading Down 0.9%

Bruker stock opened at $33.33 on Friday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 0.87 and a current ratio of 1.73. The business’s 50-day simple moving average is $41.57 and its 200-day simple moving average is $41.00. The firm has a market capitalization of $5.07 billion, a PE ratio of -222.17, a PEG ratio of 2.01 and a beta of 1.19. Bruker has a 52 week low of $28.53 and a 52 week high of $56.22.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Thursday, February 12th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.65 by ($0.06). Bruker had a positive return on equity of 13.56% and a negative net margin of 0.25%.The company had revenue of $977.20 million during the quarter, compared to analyst estimates of $964.61 million. During the same quarter in the previous year, the business posted $0.76 EPS. The company’s revenue was down .2% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Equities research analysts forecast that Bruker will post 2.69 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on BRKR shares. Weiss Ratings restated a “sell (d+)” rating on shares of Bruker in a research report on Monday, December 29th. Jefferies Financial Group set a $50.00 price target on Bruker in a report on Thursday, February 12th. The Goldman Sachs Group reduced their price target on shares of Bruker from $40.00 to $35.00 and set a “sell” rating on the stock in a research report on Friday, February 13th. Bank of America increased their price objective on shares of Bruker from $43.00 to $60.00 and gave the stock a “buy” rating in a report on Monday, December 15th. Finally, JPMorgan Chase & Co. upped their target price on shares of Bruker from $50.00 to $55.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Bruker presently has a consensus rating of “Hold” and a consensus price target of $50.38.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.